Suppr超能文献

黏附细胞耗竭促进了具有最优过继转移特性的肾癌浸润 T 细胞的扩增。

Adherent cell depletion promotes the expansion of renal cell carcinoma infiltrating T cells with optimal characteristics for adoptive transfer.

机构信息

Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, Kansas, USA.

Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA.

出版信息

J Immunother Cancer. 2020 Oct;8(2). doi: 10.1136/jitc-2020-000706.

Abstract

BACKGROUND

Tumor-infiltrating lymphocyte (TIL) therapy is a personalized cancer treatment which involves generating ex vivo cultures of tumor-reactive T cells from surgically resected tumors and administering the expanded TILs as a therapeutic infusion. Phase 1 of many TIL production protocols use aldesleukin (IL-2) alone to establish TIL cultures (termed "PreREP" (Pre-Rapid Expansion Protocol)); however, this fails to consistently produce TIL cultures from renal cell carcinoma (RCC) in a timely manner. Adding mitogenic stimulation via anti-CD3/anti-CD28 beads along with IL-2 to the fresh tumor digest (FTD) during TIL generation (termed "FTD+ beads") increases successful TIL culture rates; however, T cells produced by this method may be suboptimal for adoptive transfer. We hypothesize that adherent cell depletion (ACD) before TIL expansion will produce a superior TIL product by removing the immunosuppressive signals originating from adherent tumor and stromal cells. Here we investigate if "panning," a technique for ACD prior to TIL expansion, will impact the phenotype, functionality and/or clonality of ex vivo expanded RCC TILs.

METHODS

Tumor specimens from 55 patients who underwent radical or partial nephrectomy at the University of Kansas Medical Center (KUMC) were used to develop the panning method and an additional 19 specimens were used to validate the protocol. Next-generation sequencing, immunohistochemistry/immunocytochemistry and flow cytometry were used during method development. The phenotype, functionality and clonality of autologous TILs generated in parallel by panning, PreREP, and FTD+ beads were assessed by flow cytometry, in vitro co-culture assays, and TCRB CDR3 sequencing.

RESULTS

TIL cultures were successfully generated using the panning protocol from 15/16 clear cell, 0/1 chromophobe, and 0/2 papillary RCC samples. Significantly fewer regulatory (CD4+/CD25+/FOXP3+) (p=0.049, p=0.005), tissue-resident memory (CD8+/CD103+) (p=0.027, p=0.009), PD-1+/TIM-3+ double-positive (p=0.009, p=0.011) and TIGIT+ T cells (p=0.049, p=0.026) are generated by panning relative to PreREP and FTD+ beads respectively. Critically, a subset of TILs generated by panning were able to degranulate and/or produce interferon gamma in response to autologous tumor cells and the average tumor-reactive TIL yield was greatest when using the panning protocol.

CONCLUSIONS

Removing immunosuppressive adherent cells within an RCC digest prior to TIL expansion allow for the rapid production of tumor-reactive T cells with optimal characteristics for adoptive transfer.

摘要

背景

肿瘤浸润淋巴细胞 (TIL) 疗法是一种个性化的癌症治疗方法,涉及从手术切除的肿瘤中体外培养肿瘤反应性 T 细胞,并将扩增的 TIL 作为治疗性输注物进行输注。许多 TIL 生产方案的第 1 阶段仅使用白细胞介素 2 (IL-2) 来建立 TIL 培养物(称为“PreREP”(快速扩增前方案));然而,这不能及时从肾细胞癌 (RCC) 中产生 TIL 培养物。在 TIL 生成过程中,通过在新鲜肿瘤消化物 (FTD) 中添加有丝分裂刺激物(抗 CD3/抗 CD28 珠)和 IL-2(称为“FTD+珠”)来增加成功的 TIL 培养物率;然而,通过这种方法产生的 T 细胞可能不适合过继转移。我们假设在 TIL 扩增前进行贴壁细胞耗竭 (ACD) 将通过去除源自贴壁肿瘤和基质细胞的免疫抑制信号来产生更好的 TIL 产物。在这里,我们研究了在 TIL 扩增前进行“淘选”(一种 ACD 技术)是否会影响体外扩增的 RCC TIL 的表型、功能和/或克隆性。

方法

使用来自堪萨斯大学医学中心 (KUMC) 接受根治性或部分肾切除术的 55 名患者的肿瘤标本来开发淘选方法,并使用另外 19 份标本来验证方案。在方法开发过程中使用下一代测序、免疫组织化学/免疫细胞化学和流式细胞术。通过流式细胞术、体外共培养测定和 TCRB CDR3 测序评估平行通过淘选、PreREP 和 FTD+珠生成的自体 TIL 的表型、功能和克隆性。

结果

成功使用淘选方案从 16 个透明细胞、0 个嫌色细胞和 0 个乳头状 RCC 样本中生成 TIL 培养物。显著减少调节性 (CD4+/CD25+/FOXP3+)(p=0.049,p=0.005)、组织驻留记忆 (CD8+/CD103+)(p=0.027,p=0.009)、PD-1+/TIM-3+双阳性(p=0.009,p=0.011)和 TIGIT+T 细胞(p=0.049,p=0.026)由淘选产生,而不是 PreREP 和 FTD+珠。至关重要的是,淘选产生的 TIL 亚群能够脱颗粒和/或对自体肿瘤细胞产生干扰素γ,并且当使用淘选方案时,平均肿瘤反应性 TIL 产量最高。

结论

在 TIL 扩增前从 RCC 消化物中去除免疫抑制性贴壁细胞可以快速产生具有过继转移最佳特征的肿瘤反应性 T 细胞。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d4b/7549459/021010be42f5/jitc-2020-000706f01.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验